





















833Arq Bras Endocrinol Metab. 2010;54/9
original article
The Brazilian version of the Quality of 
Life Assessment of Growth Hormone 
Deficiency in Adults (QoL-AGHDA) – 
Four-stage translation and validation  
Versão brasileira do questionário “Quality of Life – Assessment  
of Growth Hormone Deficiency in Adults” (QoL-AGHDA) – Tradução  
e validação em quatro estágios
Antônio Ribeiro-Oliveira Jr.1*, Suélem Simão Mol1*, James Twiss2,  
Guilherme Asmar Alencar1, Paulo Augusto Carvalho Miranda3, 
Luciana A. Naves4, Monalisa F. Azevedo4, Flávia M. A. Basílio5,  
César Luiz Boguszewski5, Kátia C. Nogueira6, Lúcio Vilar7,  
Maria Koltowska-Haggstrom8, Steve P. McKenna2
ABSTRACT 
Objective: This study reports on the Brazilian Portuguese adaptation of the QoL-AGHDA (Quality 
of Life Assessment of Growth Hormone Deficiency in Adults) for use in adult growth hormone 
deficient (GHD) patients. Materials and methods: The translation process adopted the dual 
panel methodology. The questionnaire was tested through field-test interviews (16 GHD pa-
tients). In the final stage, data from 120 GHD patients (81 included in a test-retest analysis) were 
analyzed for internal consistency, test-retest reliability, convergent validity and validity among 
known groups. Results: The translation panels were successful and the draft version was amen-
ded to improve the wording as a result of the field-test interviews. Cronbach’s alpha was 0.90 
and test-retest reliability 0.88. QoL-AGHDA scores had the expected pattern of association with 
NHP scale scores and QoL-AGHDA was able to differentiate significantly between patients ba-
sed on patient-reported general health (p < 0.01) and QoL (p < 0.01). Conclusions: The adapta-
tion of the QoL-AGHDA for a Brazilian population was successful and the adapted questionnaire 
was shown to be reliable and valid. Arq Bras Endocrinol Metab. 2010;54(9):833-41
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RESUMO 
Objetivo: Este estudo relata o processo de adaptação da versão brasileira do questionário QoL-
-AGHDA (Quality of Life – Assessment of Growth Hormone Deficiency in Adults) para pacientes 
com deficiência do hormônio de crescimento (DGH). Materiais e métodos: A tradução adotou 
a metodologia de duplo painel. O questionário foi testado por intermédio de entrevistas di-
recionadas com 16 pacientes com DGH. No estágio final, dados de 120 pacientes com DGH 
(81 com teste/reteste) foram analisados para consistência interna, confiabilidade teste/reteste, 
validade convergente e validade entre grupos conhecidos. Resultados: Os grupos de tradução 
foram bem-sucedidos e a versão final foi adaptada seguindo sugestões obtidas das entrevistas 
com os 16 pacientes. O coeficiente alfa de Cronbach foi 0,90, confiabilidade teste/reteste 0,88, 
escores QoL-AGHDA se correlacionaram com o NHP (p < 0,01) e também com a saúde geral 
relatada pelos pacientes (p < 0,01). Conclusões: A adaptação do QoL-AGHDA para a população 
brasileira foi bem-sucedida, e a nova versão demonstrou ser válida e confiável. Arq Bras Endocrinol 
Metab. 2010;54(9):833-41
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QoL-AGHDA validation for Brazil
INTRODUCTION
Growth hormone deficiency (GHD) in adults is associated with decreased lean body mass tissue 
(1,2) and bone density (3), increased abdominal body 
fat (4), functional impairment (5) and a number of car-
diovascular risk factors (6-8). It impacts on patients’ 
quality of life (QoL) in a number of ways, resulting 
from increased levels of fatigue (9), social isolation 
(10), anxiety (11) and poor memory (12). GH replace-
ment therapy has been shown to improve various ab-
normalities associated with GHD (13-15), including 
QoL, which has been used in some centers as the most 
compelling reason for initiating GH therapy (16-22). 
The main measure of QoL in adult GHD is the Quality 
of Life Assessment of Growth Hormone Deficiency in 
Adults (QoL-AGHDA) (23,24).
The QoL-AGHDA was first developed in the Uni-
ted Kingdom and has since been adapted for use in 
several additional languages (24). It adopts the needs-
-based model of QoL outlined by Hunt and McKenna 
in 1992 (25). This model postulates that life gains its 
quality from the ability of individuals to satisfy his/her 
needs. It is assumed that QoL is low when few needs 
are fulfilled. In this context, poor health interferes − in 
most cases adversely − with satisfaction of needs and, 
consequently, has a negative impact on QoL. In the 
UK, the National Institute for Clinical Excellence re-
quires patients to complete the QoL-AGHDA in order 
to determine whether they should receive GH replace-
ment (26).
In Brazil, there are established guidelines to help 
clinicians judge those adults with GHD that should 
receive GH replacement. However, QoL is not part of 
the protocol-based therapeutic decision (27). The esta-
blishment of a validated GHD-specific measure of QoL 
for guiding such decisions in Brazil would be of great 
benefit. This approach would ultimately permit a more 
rational use of this high cost prolonged treatment, as 
adopted in other countries (26). In addition, with incre-
asing globalization, cross-cultural communication and 
the high number of international clinical trials, culturally 
equivalent outcome instruments available in different 
languages are crucial. Each language version must be 
culturally relevant and acceptable to the target popula-
tion and must also be psychometrically comparable.
The aim of this study was to produce a Brazilian 
Portuguese adaptation of the QoL-AGHDA that is 
conceptually equivalent to the UK-English version. 
MATERIAL AND METHODS
Content of the QoL-AGHDA was generated from in-
-depth qualitative interviews conducted with adult pa-
tients with GHD in the UK. The measure contains 25 
items that require yes/no answers. Its score is compu-
ted by summing the number of “yes” answers with high 
QoL-AGHDA scores indicating poor QoL. Question-
naires containing more than 20% missing responses are 
excluded from analyses (24).
Five language versions (English, Swedish, German, 
Italian, and Spanish) were developed simultaneous-
ly using dual translation panels (23,24). Versions for 
the United States, Belgium, Netherlands, Denmark, 
Poland, Serbia, the Czech Republic and Slovakia were 
developed later. 
The translation process adopted the dual panel me-
thodology recommended by Hunt and cols. (25,28). 
In the dual panel method quality is ensured by proces-
ses built in during each step of translation rather than 
being checked a posteriori. This methodology has been 
used in the development of all language adaptations of 
the QoL-AGHDA. It emphasizes the importance of 
achieving conceptual equivalence of translated items 
to the original. This allows the comparison of QoL-
-AGHDA scores across countries. 
The dual-panel translation and validation methodo-
logy consists of 4 stages: Stage 1: bilingual translation 
panel − to provide the initial translation into the target 
language; Stage 2: lay translation panel − where items 
are assessed for comprehension and “naturalness” of 
language; Stage 3: field-testing for face and content 
validity-performed in a small group of the target au-
dience (patients); Stage 4: assessment of psychometric 
and scaling properties.
Bilingual panel (Stage 1)
The bilingual panel was conducted at the Clinics Hos-
pital of Federal University of Minas Gerais/Brazil and 
included eight Brazilians bilingual in Portuguese and 
English. All participants had Brazilian Portuguese as 
their primary language. The purpose of this panel was 
to translate the instructions, items and response cate-
gories to the target language. The panel coordinator 
was a Professor of Medicine who represented the local 
investigator (AROJr) and his role was to ensure that no 
panel member was too dominant and to help find con-
sensus on the appropriate translations. This meeting 
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QoL-AGHDA validation for Brazil
the QoL-AGHDA (SPM), whose role was to guide the 
process and, when needed, to explain the conceptual 
meaning of the items to panel members. 
The panel worked together as a team on the trans-
lation of the QoL-AGHDA, aimed at finding the best 
form of words that could represent the original UK En-
glish instructions and items. Panel members were in-
formed of the purpose of the panel and received a brief 
description of GHD in adults, the effects of the disea-
se on QoL and the way in which the QoL-AGHDA is 
used in the evaluation of QoL in GHD patients. Panel 
members received the English version of the instrument 
a week before the translation panel meeting and they 
were asked to read it through with a view to translating, 
with the following requirements in mind; to capture 
the same concepts as the English questionnaire and to 
produce a comprehensible and acceptable formulation 
of the concept. At the meeting items were presented 
to the group one-by-one and their meaning explained.
Lay panel (Stage 2) 
The translations produced by the bilingual panel were 
considered by a group of nine Brazilians of an avera-
ge to lower than average educational level, who were 
considered to be more typical of the target population. 
The lay panel was conducted at the Clinics Hospital 
of Federal University of Minas Gerais, Brazil. None of 
the participants could speak English. All were physically 
active and lived in the State of Minas Gerais. The pur-
pose of this second panel was to ensure that the final 
wording of the items was appropriate to the patients.
Participants were presented with the translations 
made by the bilingual panel and asked to comment 
on them in terms of comprehension and acceptability. 
In particular, they were asked to decide whether the 
phrasing and language was acceptable or whether these 
should be changed to make the items more “natural”, 
while maintaining the original meaning. Again, the pa-
nel worked as a group to decide on the most appropria-
te wording. This panel had priority over the bilingual 
panel. GHD patients were excluded from the lay panel 
as its purpose was to determine the most appropriate 
wording for the questionnaire, rather than to comment 
on the appropriateness of the items.
The participants of this panel worked solely with the 
target language version of the questionnaire (Brazilian 
Portuguese). It was the role of the leader (who had also 
been the leader of the bilingual panel) to ensure that the 
original meaning was maintained in the final translation.
Procedure for Field Test Interviews (Stage 3)
The purpose of the interviews was to test the applicabi-
lity, comprehension, relevance and comprehensiveness 
of the new instrument with relevant respondents. The 
interviews took the form of one-to-one semi-structu-
red interviews with adult GHD patients.
Patients were recruited from the Department of In-
ternal Medicine (Endocrinology Centre), Federal Uni-
versity of Minas Gerais, Belo Horizonte. No patient 
had received GH therapy in the previous six months. 
Respondents were asked to complete the questio-
nnaire in the presence of an interviewer, who made a 
note of any obvious difficulties or hesitation over parti-
cular items. Interviewees were then asked to comment 
on the questionnaire items, instructions and response 
format. Specifically, respondents were asked whether 
they thought the items were relevant, applicable and 
comprehensible and if they thought any important as-
pects of their experience of GHD had been omitted. 
Once their spontaneous views had been elicited, inter-
viewees were asked specific questions about items that 
had been highlighted a priori as requiring discussion. 
These were alternative wordings for the same or similar 
concepts or items that were seen as being potentially 
problematic for some or all respondents.
Procedure for psychometric validation (Stage 4)
The data needed to establish the psychometric pro-
perties of the new version of the QoL-AGHDA were 
collected from patients with GHD. The QoL-AGHDA 
was administered via postal survey on two occasions 
(Times 1 and 2), with 15 days between administrations. 
Participants also completed the Nottingham Health 
Profile questionnaire (NHP) (29). The NHP is a gene-
ric instrument, designed to measure subjective health 
status in the following sections; physical mobility, pain, 
sleep, emotional reactions, social isolation, and energy 
level. The NHP score is presented as a profile (scores 
per individual domains as described above). An index of 
distress can also be calculated (NHP-Distress) based on 
responses to 24 of the items (30).
At the first assessment patients also answered demo-
graphic questions (gender, age, marital status, employ-
ment) and rated their general health and QoL. 
One hundred and twenty GHD patients were re-
cruited from 6 different Brazilian endocrine centers. 
From the 120 patients enrolled to this stage of valida-
tion from December 2007 to October 2009, 59 were 
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rizonte (MG), 19 were from Hospital Santa Casa, Belo 
Horizonte (MG), 19 from the University of Brasília/
Brasília (DF), 10 from the Federal University of Per-
nambuco/Recife (PE), 7 from SEMPR, the Federal 
University of Paraná/Curitiba (PR), and 6 from Hos-
pital Brigadeiro/São Paulo (SP). 
The hypopituitary patients selected were all on 
stable pituitary hormone replacement for any pituita-
ry deficit, excluding GH, in the previous six months. 
Post-menopausal women were not receiving sex steroid 
replacement. Patients with visual impairments compro-
mising reading abilities were excluded from the study. 
Responses to the completed questionnaires were ente-
red into an electronic database.
The 4Th stage of the validation process encompassed:
Internal consistency 
Internal consistency was assessed using Cronbach’s al-
pha coefficients (31,32). Alpha measures the extent to 
which items in a scale are inter-related. An alpha below 
0.7 indicates that the items do not work together to 
form a scale. 
Test-retest reliability
The test-retest reliability of a measure is an estimate of 
its reproducibility over time when no change in condi-
tion has taken place. It is assessed by correlating scores 
on the scales obtained on two different occasions. A 
high correlation (Spearman rank correlation coeffi-
cient) indicates that the instrument produces low ran-
dom measurement error. A minimum value of 0.85 is 
required where a measure is intended to be used on an 
individual basis (33). 
Convergent validity
Convergent validity can be determined by assessing the 
level of association between scores on one scale and 
those on a comparator scale that measures the same 
or a related construct. For the present investigation, 
the NHP was used as a comparator instrument. QoL-
-AGHDA scores were correlated with NHP section 
scores using Spearman rank correlation coefficients. 
Known groups validity
Known groups validity can be assessed by testing the 
ability of a measure to distinguish between groups of 
people that differ according to some known factor. The 
factors used for the present investigation were patient-
-reported general health (excellent, good, fair, poor, 
very poor) and patient-reported QoL (excellent, good, 
fair, poor, very poor). 
Statistical analysis
Results were expressed as means ± SD and/or medians 
(IRQ). Non-parametric statistical tests (Spearman Rank 
correlations, Mann-Whitney U Tests for two groups or 
Kruskal-Wallis One-Way Analysis of Variance for three 
or more groups) were employed throughout the analy-
ses due to the ordinal nature of the data. All statisti-
cal analyses were conducted using the SPSS version 16 
with p < 0.05 taken to indicate statistical significance.
Ethics
The study was approved by the Brazilian National 
Ethics Committee – Comitê Nacional de Ética em Pes-
quisa (Conep) and by the Local Ethics Committees 
from each participating institution. All the participants 
gave informed consent.
RESULTS
Bilingual panel (Stage 1)
Participant details are provided in table 1. All partici-
pants in the bilingual panel had received a university 
education.
It was not always possible to find a “natural” trans-
lation for an item in the new language. Where this was 
the case, it was necessary to find a phrase that was con-
ceptually equivalent. It was also vital that new items were 
expressed in common (everyday) language in order to 
appeal to respondents. The panel worked together to 
agree on the most appropriate translation. The group 
had the opportunity to discuss alternatives and the final 
decision on translations was taken by the group rather 
than a single researcher.
Two items required considerable discussion before 
the panel came to a conclusion on the most appropriate 
wording. The first, I have to read things several times 
before they sink in was expressed in terms of difficulty 
for the person to get an idea into their head rather than 
being directly related to memory − Eu tenho de ler as 
coisas várias vezes para conseguir gravá-las.
The second item was I find it hard to mix with peo-
ple. Difficulty was found with this item as it is unusual 
for people to be lonely in Brazil as compared to Eu-
ropean countries. It was translated in a way that gives 
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the impression that is hard to have a good relationship 
with others in daily life − Eu acho difícil conviver com 
as outras pessoas. It was not found necessary to send 
alternative versions of any item or instruction for consi-
deration by the subsequent lay panel.
The meeting lasted just over two hours.
Lay panel (Stage 2)
Participant details are shown in table 1. All participants 
in the lay panel had an average to below average edu-
cation level.
Participants worked together to improve the struc-
turing of some of the translations suggested by the bi-
lingual panel. However, only minor changes needed to 
be made before the questionnaire was ready for field-
-testing. 
The lay panel lasted one hour and forty-five minutes.
Cognitive debriefing interviews (Stage 3)
Participant details are shown in table 1.
Overall the measure was well accepted by inter-
viewees. Some small changes were suggested to impro-
ve wording. For example Eu (I) was added to many 
of the items in order to stress the importance of the 
participants’ own views. In addition, alternative endings 
were provided for pronouns and adjectives to cater for 
the gender of the respondent. Each interview lasted a 
mean of 20 ± 4 minutes. In addition, some patients 
expressed a desire for a ‘sometimes’ option. In these 
cases, participants were reminded that the instructions 
asked them to consider how they feel at the moment. 
A few patients skipped some questions and returned to 
them later.
One specific item caused concern for several inter-
viewees − Eu tenho de me obrigar a fazer tudo aquilo 
que preciso (I have to push myself to do things). The idea 
of obliging oneself suggested by the panels was found 
to be difficult to understand by some interviewees. The 
item was changed to Eu tenho de me esforçar para fa-
zer tudo o que preciso which equates to ‘I have to make 
strong efforts to do my own tasks’.
Sample items from the final version of the QoL-
-AGHDA in Brazilian Portuguese are shown in Appen-
dix 1.
Psychometric validation (Stage 4)
Descriptive statistics 
The demographic and disease information for the sur-
vey participants is shown in table 2. Approximately 
60% of the sample was female. The mean age was 46.3 
(range = 18-85) years, with over half married or living 
as married. The educational level was low – a third of 
respondents had gone to university. All of them had 
low age-adjusted IGF-1 levels coupled to two or more 
pituitary deficits, or GH after an insulin tolerance test 
lower than 3 µg/L (14). None of them had any im-
portant neurological deficit that could compromise un-
derstanding or reading ability of the questionnaire.
Out of the 120 patients, 79 (65.8%) had undergone 
pituitary surgery. Thirty-six were from non-secreting 
adenomas (45.6%), 14 craniopharyngiomas (17.7%), 
12 prolactin-secreting adenomas (15.2%), 5 ACTH 
secreting-adenomas (6.3%), and 12 from other causes 
(ependimoma, meningioma, apoplexy, arachnoid cyst, 
trauma, sarcoidosis) (15.2%). These numbers are simi-
lar to those reported in the literature, where non-secre-
ting pituitary macroadenomas and craniopharyngiomas 
are found to be the most prevalent causes of pituitary 
Table 1. Bilingual panel, lay panel and cognitive debriefing demographic details
Bilingual panel Lay panel Cognitive debriefing
n 8 9 16
Gender
Male (%) 4 (50.0%) 3 (33.3%) 9 (56.3%)
Age (years)
Mean (SD) 30.4 (5.1) 42.6 (13.7) 47.1 (20.6)
Median (IQR) 28.5 (27.0-34.8) 45.0 (28.5-53.5) 49.0 (25.8-71.3)
Range 25-40 23-62 20-75
SD: standard deviation; IQR: inter-quartile range.
In total, 16 adult GHD patients were interviewed 
by the authors (AROJr, SSM and GAA) at the Federal 
University of Minas Gerais in the first semester of 2007. 
All these patients had low age-adjusted insulin-like gro-
wth factor-1 (IGF-1) coupled to two or more pituitary 
deficits (14). None of them had any neurological deficit 
that could compromise understanding or reading abili-
ty of the questionnaire. The interviews took place in a 
quiet room at the Endocrinology centre. 
All interviewees were clear about the purpose of the 
interview and read the instructions before starting to 
complete the measure. None of the respondents failed 
to understand the instructions, none of the questions 
were deemed inappropriate and none of the interviewees 
reported that important aspects of their experience had 
been omitted from the questionnaire.
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Table 2. Demographic and disease information for patients participating in 
the psychometric validation (stage four)
Gender
Male (%) 46 (38.3)
Female (%) 72 (60.0)
Missing (%) 2 (1.7)
Age (years)
Mean (SD) 46.3 (15.2)
Range 18-85
Educational level (%)
Primary (5-10/11 years) 47 (39.2)
Secondary (11-15/16 years) 31 (25.8)












Duration of GHD (years)
















GHD: growth hormone deficiency; SD: standard deviation; QoL: quality of life.
surgery and morbidity (34,35). Twenty-six (32.9%) 
of these patients had also undergone radiotherapy. Of 
those patients who had not had surgery, 23 (56.1%) 
had GHD due to Sheehan syndrome, followed by idio-
pathic childhood-onset GHD.
Concerning pituitary deficits, 8.3% (10 patients) 
had only GH deficiency, 15.8% (19 patients) had 2 
pituitary deficits, 13.3% (16 patients) had 3 pituitary 
deficits, and the remainder 62.5% (75 patients) had pa-
nhypopituitarism. Thirteen out of those 75 panhypo-
pituitary patients (17.3%) also had diabetes insipidus. 
This is also similar to what has been reported in the 
literature for other GHD populations (36-38).
Eighty-one individuals (67.5%) completed the 
questionnaire on both occasions. The low completion 
rate at Time 2 was because the study was stopped when 
a sufficient sized sample for test-retest purposes was 
achieved. The subgroup that did not complete the me-
asure at the second time point did not differ significan-
tly from the rest of the sample in terms of age, gender 
or Time 1 QoL-AGHDA score. 
Table 3 shows QoL-AGHDA scores at Times 1 and 2. 
Minimal levels of ceiling and floor effects were found 
indicating that the items were well targeted to the sam-
ple. In addition, the score distributions at the item level 
were good, with no items attracting all ‘true’ or all ‘un-
true’ responses.
Table 3. QoL AGHDA descriptive statistics 

















SD: standard deviation; IQR: inter-quartile range.
QoL-AGHDA validation for Brazil
Internal consistency
The Cronbach’s alpha coefficients for internal consis-
tency were 0.90 and 0.92 for Times 1 and 2. This sho-
ws that the instrument had good inter-relatedness of 
items. In addition, all of the CITCs at Time 1 were 
between 0.2 and 0.8, indicating that no items were un-
related to or redundant within the scale. At Time 2 two 
items had ITCs below 0.2. As this occurred at only one 
time point these items were not considered problema-
tic. The statistics also showed that the removal of any 
individual item would not have increased the overall 
alpha coefficient of the scale at either time point.
Test-retest reliability
The test-retest reliability for the QoL-AGHDA was 
0.88, indicating that the scale produces low levels of 
random measurement error. This in turn suggests that 
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Convergent validity
Table 4 shows the correlations between scores on the 
QoL-AGHDA and those on the NHP. As expected, the 
QoL-AGHDA correlated higher with the Energy level, 
Emotional reactions and Social isolation sections, con-
firming findings from other studies (24). There were 
low correlations between the QoL-AGHDA and the 
Pain and Sleep scales. In addition, the QoL-AGHDA 
had a moderately high correlation with NHP-Distress. 
subsequent lay panel found the content of the trans-
lation easy to understand and decisions on its suitabi-
lity were reached with little discussion. Participants in 
the field testing interviews agreed the content of the 
questionnaire was good and covered relevant aspects 
of patients’ experience. Useful suggestions were made 
by the interviewees to improve the wording of certain 
items. 
The final version of the measure was then tested 
psychometrically with adult GHD patients. The valida-
tion survey involved 120 patients from multiple centers 
who were representative of the Brazilian GHD popu-
lation. These patients were similar to those enrolled 
for validation of the QoL-AGHDA in other countries 
(35,37-39). Sixty-seven point five percent (67.5%) of 
the sample completed the QoL-AGHDA at both admi-
nistrations. The low number of completions at Time 2 is 
due to the study having been stopped when a sufficient 
number of participants had been recruited at Time 2 
for test-retest purposes. Score distributions were good 
with minimal levels of floor or ceiling effects. This indi-
cates that the items are well targeted to the severity of 
the GHD patients. 
Cronbach’s alpha coefficients were above 0.9 for the 
QoL-AGHDA demonstrating that the items work to-
gether to form a scale. Where problems did exist, they 
tended to occur with single items at one time point 
only. The test-retest reliability of the QoL-AGHDA 
was excellent. The convergent validity of the measure 
was also supported as the results showed similar cor-
relations to NHP sections as have been observed with 
other language versions of the QoL-AGHDA. The 
QoL-AGHDA was also able to distinguish between pa-
tients according to their perceptions of general health 
and QoL.
Overall the results show that the new language ver-
sion of the QoL-AGHDA is conceptually equivalent to 
the UK-English version. When compared to other Eu-
ropean countries, where the same adaptation methodo-
logy was applied, the results are comparable (19,24). 
Interestingly, the median Brazilian QoL-AGHDA sco-
re was 11, comparable to the same median score ob-
tained for the UK, which was 10, but higher than ob-
served for other European countries such as Sweden, 
Italy, Spain, and Germany (median scores; 8, 8, 5, and 
4, respectively) (24). 
The study was designed to achieve as representative 
a Brazilian adaptation as possible. The translated ques-
tionnaire was produced using the two-panel methodo-





Excellent 5.2 (3.1) 6.8 (6.0)
Good 9.7 (6.4) 11.0 (5.7)
Fair 14.0 (6.0) 13.4 (6.7)
Poor/very poor 18.6 (5.9) 19.1 (6.3)
P < 0.001 < 0.001
SD: standard deviation.
Table 4. Correlation coefficients between QoL-AGHDA and NHP sections
Time 1 Time 2
NHP
Energy level 0.70 0.72
Pain 0.43 0.38
Emotional reactions 0.79 0.81
Sleep 0.41 0.34
Social isolation 0.69 0.70
Physical mobility 0.52 0.46
NHP-D 0.79 0.79
All correlations significant p < 0.01; NHP-D: NHP-distress.
Validity among known groups
Table 5 shows the relations between QoL-AGHDA 
scores and self-reported general health and QoL. Hi-
gher scores were associated with poorer general health 
and QoL (p < 0.001). There was no relation between 
the QoL-AGHDA scores and gender or age.
QoL-AGHDA validation for Brazil
DISCUSSION
The adaptation of the QoL-AGHDA for a Brazilian po-
pulation, via the 4-stage process, was successful. The 
measure was amenable to translation into Brazilian 
Portuguese and the translation was found to provide a 
reproducible and valid measure of the impact of GHD 
on the lives of affected patients. 
The bilingual panel meeting progressed well and all 
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logy which is superior to a forward-backward approach 
in taking account cross-cultural differences between 
countries. Furthermore, the validation study included 
patients from five different regions. However, the pre-
sent study was not designed to assess the responsiveness 
of the Brazilian QoL-AGHDA or assess its relation to 
other clinical factors. Future studies are needed to in-
vestigate these issues.
In conclusion, the Brazilian Portuguese version of 
the QoL-AGHDA is a reliable and valid measure of 
QoL, suitable for inclusion in clinical studies and rou-
tine clinical practice. This instrument may ultimately 
help clinical decision making concerning the use of GH 
therapy for adult GHD patients.
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The full Brazilian QoL-AGHDA cannot be published herein for copyright reasons 
and to maintain the quality of future adaptations. People wishing to use the 
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Sample items:
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